Dr. Reddy's Laboratories (RDY) Financials

$14.74 +0.19 (+1.27%)

Closing price 05/29/2025 03:59 PM Eastern

Extended Trading

$14.74 0.00 (-0.03%)

As of 05/29/2025 07:52 PM Eastern

Annual Income Statements for Dr. Reddy's Laboratories

This table shows Dr. Reddy's Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017	3/31/2016
Net Income / (Loss) Attributable to Common Shareholders	55,684	45,067	23,568	0.00	0.00	272	-129,548	186	302
Consolidated Net Income / (Loss)	55,684	45,067	23,568	0.00	0.00	272	9,806	186	302
Net Income / (Loss) Continuing Operations	55,684	45,067	23,568	0.00	0.00	272	-129,548	186	302
Total Pre-Tax Income	71,870	60,367	32,298	0.00	0.00	325	-129,478	226	410
Total Operating Income	67,729	57,144	29,476	0.00	0.00	302	-128,661	208	447
Total Gross Profit	163,607	139,343	113,840	0.00	0.00	1,206	76,304	1,208	1,393
Total Revenue	279,164	245,879	214,391	0.00	0.00	2,225	2,226	2,171	2,335
Operating Revenue	279,164	245,879	214,391	0.00	0.00	2,225	2,226	2,171	2,335
Total Cost of Revenue	115,557	106,536	100,551	0.00	0.00	1,018	65,724	963	942
Operating Cost of Revenue	115,557	106,536	100,551	0.00	0.00	1,018	65,724	963	942
Total Operating Expenses	95,878	82,199	84,364	0.00	0.00	904	65,163	1,000	946
Selling, General & Admin Expense	77,201	68,026	62,081	0.00	0.00	704	46,857	715	690
Research & Development Expense	22,873	19,381	17,482	0.00	0.00	226	18,265	301	269
Exploration Expense	3.00	699	7,562	0.00	0.00	3.04	-	-	-
Other Operating Expenses / (Income)	-4,199	-5,907	-2,761	0.00	0.00	-28	-12	-16	-13
Total Other Income / (Expense), net	4,141	3,223	2,822	0.00	0.00	22	-817	18	-37
Interest Expense	1,711	1,428	958	0.00	0.00	17	-	12	75
Interest & Investment Income	5,705	4,281	3,077	0.00	0.00	33	-	24	34
Other Income / (Expense), net	147	370	703	0.00	0.00	6.33	-817	5.38	3.46
Income Tax Expense	16,186	15,300	8,730	0.00	0.00	53	70	40	108
Basic Earnings per Share	$334.65	$271.43	$142.08	$103.94	$117.63	$113.28	$59.13	$72.24	$117.34
Weighted Average Basic Shares Outstanding	166.82M	166.53M	166.43M	166.30M	166.17M	166.07M	165.91M	-	170.55M
Diluted Earnings per Share	$334.02	$270.85	$141.69	$103.65	$117.40	$113.09	$0.91	$72.09	$116.98
Weighted Average Diluted Shares Outstanding	166.82M	166.53M	166.43M	166.30M	166.17M	166.07M	165.91M	-	171.07M
Weighted Average Basic & Diluted Shares Outstanding	166.82M	166.53M	166.43M	166.30M	166.17M	166.07M	165.91M	-	-

No quarterly income statements for Dr. Reddy's Laboratories are available.

This table details how cash moves in and out of Dr. Reddy's Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017	3/31/2016
Net Change in Cash & Equivalents	1,387	-9,359	-701	0.00	0.00	-5.05	-1,294	-10	58
Net Cash From Operating Activities	45,433	58,875	28,108	0.00	0.00	415	18,029	-332	623
Net Cash From Continuing Operating Activities	45,433	58,875	28,108	0.00	0.00	415	17,223	332	623
Net Income / (Loss) Continuing Operations	55,684	45,067	23,568	0.00	0.00	272	9,806	186	302
Consolidated Net Income / (Loss)	55,684	45,067	23,568	0.00	0.00	272	9,806	186	302
Depreciation Expense	14,841	12,636	11,824	0.00	0.00	176	11,710	174	155
Non-Cash Adjustments To Reconcile Net Income	15,137	19,741	18,651	0.00	0.00	10	1,784	143	274
Changes in Operating Assets and Liabilities, net	-40,229	-18,569	-25,935	0.00	0.00	-43	-6,077	-171	-108
Net Cash From Investing Activities	-40,283	-41,373	-26,387	0.00	0.00	-112	-14,883	-285	-308
Net Cash From Continuing Investing Activities	-40,283	-41,373	-26,387	0.00	0.00	-112	-14,883	-285	-308
Purchase of Property, Plant & Equipment	-27,435	-18,866	-19,049	0.00	0.00	-121	-11,043	-632	-43
Acquisitions	0.00	0.00	-326	0.00	0.00	0.00	-	-0.26	-120
Purchase of Investments	-145,500	-136,171	-88,972	0.00	0.00	-1,136	-68,429	-767	-1,030
Sale of Property, Plant & Equipment	1,085	82	3,316	0.00	0.00	31	139	0.68	-180
Sale and/or Maturity of Investments	131,567	113,582	78,644	0.00	0.00	1,114	64,450	1,114	1,065
Net Cash From Financing Activities	-3,763	-26,861	-2,422	0.00	0.00	-308	-4,440	-57	-257
Net Cash From Continuing Financing Activities	-3,421	-26,214	-1,971	0.00	0.00	-308	-4,440	-57	-257
Repayment of Debt	-573	-21,235	2,175	0.00	0.00	-243	-449	-4.67	-195
Payment of Dividends	-6,648	-4,979	-4,146	0.00	0.00	-58	-3,992	-52	-62
Issuance of Debt	3,800	0.00	0.00	0.00	0.00	0.00	-	-	-

No quarterly cash flow statements for Dr. Reddy's Laboratories are available.

This table presents Dr. Reddy's Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017
Total Assets	387,518	321,854	0.00	0.00	3,081	225,427	3,465	3,390
Total Current Assets	248,049	204,253	0.00	0.00	1,729	114,501	1,684	1,548
Cash & Equivalents	7,107	5,779	0.00	0.00	27	2,228	41	60
Short-Term Investments	74,365	56,033	0.00	0.00	329	22,889	283	224
Accounts Receivable	80,298	72,485	0.00	0.00	667	39,869	624	587
Inventories, net	63,552	48,670	0.00	0.00	465	486	447	440
Other Current Assets	22,560	20,069	0.00	0.00	183	12,536	220	185
Plant, Property, & Equipment, net	76,886	66,462	0.00	0.00	694	54,088	889	881
Plant, Property & Equipment, gross	76,886	66,462	0.00	0.00	694	54,088	889	881
Total Noncurrent Assets	58,865	48,452	0.00	0.00	657	13,113	892	960
Long-Term Investments	5,255	5,362	0.00	0.00	41	3,342	71	105
Goodwill	4,253	4,245	0.00	0.00	53	3,902	61	58
Intangible Assets	36,951	30,849	0.00	0.00	367	642	686	693
Noncurrent Deferred & Refundable Income Taxes	10,774	7,196	0.00	0.00	162	4,168	56	86
Other Noncurrent Operating Assets	1,632	800	0.00	0.00	34	1,059	18	18
Total Liabilities & Shareholders' Equity	387,518	321,854	0.00	0.00	3,081	225,427	3,465	3,390
Total Liabilities	106,968	90,863	0.00	0.00	1,025	85,230	1,523	1,477
Total Current Liabilities	96,039	85,845	0.00	0.00	966	59,700	1,070	1,311
Short-Term Debt	14,030	12,194	0.00	0.00	275	237	392	673
Accounts Payable	30,919	26,444	0.00	0.00	221	14,613	247	207
Current Deferred & Payable Income Tax Liabilities	2,342	2,144	0.00	0.00	7.60	181	23	23
Other Current Liabilities	48,286	44,928	0.00	0.00	463	24,419	408	408
Total Noncurrent Liabilities	10,929	5,018	0.00	0.00	59	25,530	452	166
Long-Term Debt	5,990	1,278	0.00	0.00	17	318	385	84
Noncurrent Deferred & Payable Income Tax Liabilities	909	833	0.00	0.00	3.65	610	11	19
Other Noncurrent Operating Liabilities	4,030	2,907	0.00	0.00	38	42	56	63
Total Equity & Noncontrolling Interests	280,550	230,991	0.00	0.00	2,056	140,197	1,942	1,913
Total Preferred & Common Equity	280,550	230,611	0.00	0.00	2,056	139,379	1,942	1,913
Preferred Stock	10,765	9,688	0.00	0.00	113	8,211	120	113
Total Common Equity	269,785	220,923	0.00	0.00	1,943	131,168	1,823	1,799
Common Stock	834	833	0.00	0.00	11	12	13	13
Retained Earnings	265,257	215,593	0.00	0.00	1,913	128,646	1,749	1,666
Treasury Stock	-991	-1,269	0.00	0.00	-13	-535	0.00	-
Other Equity Adjustments	4,685	5,766	0.00	0.00	32	3,045	61	120

No quarterly balance sheets for Dr. Reddy's Laboratories are available.

This table displays calculated financial ratios and metrics derived from Dr. Reddy's Laboratories' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	3/31/2024	3/31/2023	3/31/2022	3/31/2021	3/31/2020	3/31/2019	3/31/2018	3/31/2017	3/31/2016
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	13.54%	14.69%	0.00%	0.00%	-100.00%	1.98%	2.51%	-7.02%	0.00%
EBITDA Growth	17.91%	67.01%	0.00%	0.00%	-100.00%	31.63%	-30,498.26%	-35.99%	0.00%
EBIT Growth	18.02%	90.58%	0.00%	0.00%	-100.00%	63.75%	-60,738.78%	-52.61%	0.00%
NOPAT Growth	23.01%	98.34%	0.00%	0.00%	-100.00%	102.10%	-52,764.97%	-48.13%	0.00%
Net Income Growth	23.56%	91.22%	0.00%	0.00%	-100.00%	80.44%	5,182.16%	-38.55%	0.00%
EPS Growth	23.32%	91.16%	36.70%	-11.71%	3.81%	91.68%	-98.74%	-38.37%	0.00%
Operating Cash Flow Growth	-22.83%	109.46%	0.00%	0.00%	-100.00%	49.89%	5,534.76%	-153.28%	0.00%
Free Cash Flow Firm Growth	111.90%	-708.40%	1,002.62%	787.05%	-45.96%	396.27%	-4,169.56%	0.00%	0.00%
Invested Capital Growth	21.27%	0.00%	0.00%	-100.00%	-10.13%	-6.62%	1.89%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	58.61%	56.67%	53.10%	0.00%	0.00%	54.23%	3,428.09%	55.65%	59.65%
EBITDA Margin	29.63%	28.53%	19.59%	0.00%	0.00%	21.78%	-5,290.93%	17.84%	25.92%
Operating Margin	24.26%	23.24%	13.75%	0.00%	0.00%	13.58%	-5,780.31%	9.59%	19.15%
EBIT Margin	24.31%	23.39%	14.08%	0.00%	0.00%	13.86%	-5,817.02%	9.83%	19.29%
Profit (Net Income) Margin	19.95%	18.33%	10.99%	0.00%	0.00%	12.22%	440.55%	8.55%	12.94%
Tax Burden Percent	77.48%	74.66%	72.97%	0.00%	0.00%	83.75%	-7.57%	82.16%	73.74%
Interest Burden Percent	105.88%	104.96%	107.02%	0.00%	0.00%	105.24%	100.00%	105.82%	90.93%
Effective Tax Rate	22.52%	25.35%	27.03%	0.00%	0.00%	16.25%	0.00%	17.84%	26.26%
Return on Invested Capital (ROIC)	27.34%	49.17%	0.00%	0.00%	0.00%	11.25%	-3,910.65%	14.99%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	22.31%	40.80%	0.00%	0.00%	0.00%	18.42%	22,685.96%	22.93%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-5.56%	-10.15%	0.00%	0.00%	0.00%	2.44%	4,419.39%	4.42%	0.00%
Return on Equity (ROE)	21.77%	39.02%	0.00%	0.00%	0.00%	13.69%	508.74%	19.41%	0.00%
Cash Return on Invested Capital (CROIC)	8.11%	-150.83%	0.00%	200.00%	10.67%	18.10%	-3,912.52%	-185.01%	0.00%
Operating Return on Assets (OROA)	19.14%	35.74%	0.00%	0.00%	0.00%	9.17%	-3,777.82%	6.30%	0.00%
Return on Assets (ROA)	15.70%	28.00%	0.00%	0.00%	0.00%	8.08%	286.11%	5.48%	0.00%
Return on Common Equity (ROCE)	20.88%	37.32%	0.00%	0.00%	0.00%	12.87%	477.97%	18.26%	0.00%
Return on Equity Simple (ROE_SIMPLE)	19.85%	19.54%	0.00%	0.00%	0.00%	13.41%	504.88%	9.71%	0.00%
Net Operating Profit after Tax (NOPAT)	52,476	42,661	21,509	0.00	0.00	253	-90,063	171	330
NOPAT Margin	18.80%	17.35%	10.03%	0.00%	0.00%	11.37%	-4,046.22%	7.88%	14.12%
Net Nonoperating Expense Percent (NNEP)	5.03%	8.37%	0.00%	0.00%	0.00%	-7.16%	-26,596.61%	-7.94%	0.00%
Cost of Revenue to Revenue	41.39%	43.33%	46.90%	0.00%	0.00%	45.77%	2,952.76%	44.35%	40.35%
SG&A Expenses to Revenue	27.65%	27.67%	28.96%	0.00%	0.00%	31.64%	2,105.13%	32.93%	29.54%
R&D to Revenue	8.19%	7.88%	8.15%	0.00%	0.00%	10.14%	820.59%	13.88%	11.53%
Operating Expenses to Revenue	34.34%	33.43%	39.35%	0.00%	0.00%	40.65%	2,927.55%	46.06%	40.50%
Earnings before Interest and Taxes (EBIT)	67,876	57,514	30,179	0.00	0.00	308	-129,478	214	451
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	82,717	70,150	42,003	0.00	0.00	485	-117,768	387	605
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.05	0.04	0.00	0.00	3.29	3.34	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.05	0.05	0.00	0.00	4.20	5.26	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.04	0.04	0.04	0.00	0.00	2.86	0.00	0.00	0.00
Price to Earnings (P/E)	0.22	0.21	0.38	0.00	0.00	23.45	0.00	0.00	0.00
Dividend Yield	1.33%	1.36%	1.25%	0.56%	0.73%	0.76%	1.02%	0.80%	1.44%
Earnings Yield	455.87%	482.82%	261.87%	0.00%	0.00%	4.26%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	3.28	3.06	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.04	0.00	0.00	2.98	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.21	0.00	0.00	13.69	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.30	0.00	0.00	21.52	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.42	0.00	0.00	26.23	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.32	0.00	0.00	15.98	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.42	5.03	29.13	16.30	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.07	0.06	0.00	0.00	0.14	0.27	0.40	0.40	0.00
Long-Term Debt to Equity	0.02	0.01	0.00	0.00	0.01	0.16	0.20	0.04	0.00
Financial Leverage	-0.25	-0.25	0.00	-0.05	0.01	0.13	0.19	0.19	0.00
Leverage Ratio	1.39	1.39	0.00	1.50	1.55	1.69	1.78	1.77	0.00
Compound Leverage Factor	1.47	1.46	0.00	0.00	0.00	1.78	1.78	1.88	0.00
Debt to Total Capital	6.66%	5.51%	0.00%	0.00%	12.44%	21.49%	28.59%	28.36%	0.00%
Short-Term Debt to Total Capital	4.67%	4.99%	0.00%	0.00%	11.70%	9.17%	14.42%	25.21%	0.00%
Long-Term Debt to Total Capital	1.99%	0.52%	0.00%	0.00%	0.74%	12.32%	14.17%	3.15%	0.00%
Preferred Equity to Total Capital	3.58%	3.96%	0.00%	0.00%	4.80%	4.60%	4.40%	4.25%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	89.76%	90.37%	0.00%	0.00%	82.76%	73.91%	67.02%	67.39%	0.00%
Debt to EBITDA	0.24	0.19	0.00	0.00	0.00	1.15	-0.01	1.95	0.00
Net Debt to EBITDA	-0.81	-0.77	0.00	0.00	0.00	0.30	0.00	0.95	0.00
Long-Term Debt to EBITDA	0.07	0.02	0.00	0.00	0.00	0.66	0.00	0.22	0.00
Debt to NOPAT	0.38	0.32	0.00	0.00	0.00	2.19	-0.01	4.43	0.00
Net Debt to NOPAT	-1.27	-1.26	0.00	0.00	0.00	0.57	0.00	2.15	0.00
Long-Term Debt to NOPAT	0.11	0.03	0.00	0.00	0.00	1.26	0.00	0.49	0.00
Altman Z-Score	2.80	2.79	0.00	0.00	4.91	5.19	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	4.07%	4.36%	0.00%	5.48%	5.67%	6.01%	6.05%	5.93%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	2.58	2.38	0.00	0.00	1.79	1.92	1.57	1.18	0.00
Quick Ratio	1.68	1.56	0.00	0.00	1.06	1.09	0.89	0.66	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	15,576	-130,859	21,509	1,951	220	407	-90,106	-2,110	0.00
Operating Cash Flow to CapEx	172.42%	313.43%	178.66%	0.00%	0.00%	461.03%	165.34%	-52.55%	278.87%
Free Cash Flow to Firm to Interest Expense	9.10	-91.64	22.45	0.00	0.00	24.20	0.00	-175.24	0.00
Operating Cash Flow to Interest Expense	26.55	41.23	29.34	0.00	0.00	24.68	0.00	-27.55	8.32
Operating Cash Flow Less CapEx to Interest Expense	11.15	28.07	12.92	0.00	0.00	19.33	0.00	-79.97	5.33
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.79	1.53	0.00	0.00	0.00	0.66	0.65	0.64	0.00
Accounts Receivable Turnover	3.65	0.00	0.00	0.00	0.00	3.71	3.68	3.70	0.00
Inventory Turnover	2.06	0.00	0.00	0.00	0.00	2.18	148.25	2.19	0.00
Fixed Asset Turnover	3.89	0.00	0.00	0.00	0.00	2.66	2.51	2.46	0.00
Accounts Payable Turnover	4.03	0.00	0.00	0.00	0.00	4.46	289.90	4.65	0.00
Days Sales Outstanding (DSO)	99.88	0.00	0.00	0.00	0.00	98.47	99.27	98.67	0.00
Days Inventory Outstanding (DIO)	177.23	0.00	0.00	0.00	0.00	167.10	2.46	166.73	0.00
Days Payable Outstanding (DPO)	90.59	0.00	0.00	0.00	0.00	81.90	1.26	78.41	0.00
Cash Conversion Cycle (CCC)	186.52	0.00	0.00	0.00	0.00	183.67	100.48	186.99	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	210,420	173,520	0.00	0.00	1,951	2,171	2,325	2,281	0.00
Invested Capital Turnover	1.45	2.83	0.00	0.00	0.00	0.99	0.97	1.90	0.00
Increase / (Decrease) in Invested Capital	36,900	173,520	0.00	-1,951	-220	-154	43	2,281	0.00
Enterprise Value (EV)	-43,727	-34,680	9,000	9,808	6,406	6,634	0.00	0.00	0.00
Market Capitalization	12,215	9,334	9,000	9,808	6,398	6,372	0.00	0.00	0.00
Book Value per Share	$1,620.06	$1,327.46	$0.00	$0.00	$11.70	$11.50	$10.99	$10.80	$0.00
Tangible Book Value per Share	$1,372.63	$1,116.59	$0.00	$0.00	$9.17	$7.30	$6.49	$6.29	$0.00
Total Capital	300,570	244,463	0.00	0.00	2,348	2,582	2,720	2,670	0.00
Total Debt	20,020	13,472	0.00	0.00	292	555	777	757	0.00
Total Long-Term Debt	5,990	1,278	0.00	0.00	17	318	385	84	0.00
Net Debt	-66,707	-53,702	0.00	0.00	-105	143	382	368	0.00
Capital Expenditures (CapEx)	26,350	18,784	15,733	0.00	0.00	90	10,904	631	223
Debt-free, Cash-free Net Working Capital (DFCFNWC)	84,568	68,790	0.00	0.00	682	666	682	626	0.00
Debt-free Net Working Capital (DFNWC)	166,040	130,602	0.00	0.00	1,038	1,029	1,006	910	0.00
Net Working Capital (NWC)	152,010	118,408	0.00	0.00	763	792	614	237	0.00
Net Nonoperating Expense (NNE)	-3,208	-2,406	-2,059	0.00	0.00	-19	-99,869	-15	28
Net Nonoperating Obligations (NNO)	-70,130	-57,471	0.00	0.00	-105	143	382	369	0.00
Total Depreciation and Amortization (D&A)	14,841	12,636	11,824	0.00	0.00	176	11,710	174	155
Debt-free, Cash-free Net Working Capital to Revenue	30.29%	27.98%	0.00%	0.00%	0.00%	29.94%	30.64%	28.85%	0.00%
Debt-free Net Working Capital to Revenue	59.48%	53.12%	0.00%	0.00%	0.00%	46.27%	45.18%	41.92%	0.00%
Net Working Capital to Revenue	54.45%	48.16%	0.00%	0.00%	0.00%	35.62%	27.57%	10.92%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$334.65	$271.43	$142.08	$1.42	$117.63	$113.28	$0.91	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	166.82M	166.53M	166.43M	166.30M	166.17M	166.07M	165.85M	0.00	0.00
Adjusted Diluted Earnings per Share	$334.02	$270.85	$141.69	$1.52	$1.56	$113.09	$0.91	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	166.82M	166.53M	166.43M	166.30M	166.17M	166.07M	166.19M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	166.82M	166.53M	166.43M	166.30M	166.17M	166.07M	165.91M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	52,476	42,661	21,509	0.00	0.00	253	-90,026	171	330
Normalized NOPAT Margin	18.80%	17.35%	10.03%	0.00%	0.00%	11.37%	-4,044.55%	7.88%	14.12%
Pre Tax Income Margin	25.74%	24.55%	15.07%	0.00%	0.00%	14.59%	-5,817.02%	10.41%	17.54%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	39.67	40.28	31.50	0.00	0.00	18.34	0.00	17.73	6.02
NOPAT to Interest Expense	30.67	29.87	22.45	0.00	0.00	15.04	0.00	14.20	4.40
EBIT Less CapEx to Interest Expense	24.27	27.12	15.08	0.00	0.00	12.98	0.00	-34.69	3.04
NOPAT Less CapEx to Interest Expense	15.27	16.72	6.03	0.00	0.00	9.69	0.00	-38.22	1.42
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	11.94%	11.05%	17.59%	0.00%	0.00%	21.29%	40.71%	28.16%	20.52%
Augmented Payout Ratio	11.94%	11.05%	17.59%	0.00%	0.00%	21.29%	40.71%	28.16%	20.52%

No quarterly metrics and ratios for Dr. Reddy's Laboratories are available.

Frequently Asked Questions About Dr. Reddy's Laboratories' Financials

When does Dr. Reddy's Laboratories's fiscal year end?

According to the most recent income statement we have on file, Dr. Reddy's Laboratories' financial year ends in March. Their financial year 2024 ended on March 31, 2024.

How has Dr. Reddy's Laboratories' net income changed over the last 8 years?

Dr. Reddy's Laboratories' net income appears to be on an upward trend, with a most recent value of $55.68 billion in 2024, rising from $302.08 million in 2016. The previous period was $45.07 billion in 2023. View Dr. Reddy's Laboratories' forecast to see where analysts expect Dr. Reddy's Laboratories to go next.

What is Dr. Reddy's Laboratories's operating income?

Dr. Reddy's Laboratories's total operating income in 2024 was $67.73 billion, based on the following breakdown:

Total Gross Profit: $163.61 billion
Total Operating Expenses: $95.88 billion

How has Dr. Reddy's Laboratories revenue changed over the last 8 years?

Over the last 8 years, Dr. Reddy's Laboratories' total revenue changed from $2.34 billion in 2016 to $279.16 billion in 2024, a change of 11,854.5%.

How much debt does Dr. Reddy's Laboratories have?

Dr. Reddy's Laboratories' total liabilities were at $106.97 billion at the end of 2024, a 17.7% increase from 2023, and a 7,142.7% increase since 2017.

How much cash does Dr. Reddy's Laboratories have?

In the past 7 years, Dr. Reddy's Laboratories' cash and equivalents has ranged from $0.00 in 2021 to $7.11 billion in 2024, and is currently $7.11 billion as of their latest financial filing in 2024.

How has Dr. Reddy's Laboratories' book value per share changed over the last 8 years?

Over the last 8 years, Dr. Reddy's Laboratories' book value per share changed from 0.00 in 2016 to 1,620.06 in 2024, a change of 162,005.9%.

Related Companies

This page (NYSE:RDY) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Reddy's Laboratories (RDY) Financials

Frequently Asked Questions About Dr. Reddy's Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Reddy's Laboratories (RDY) Financials

Annual Income Statements for Dr. Reddy's Laboratories

Quarterly Income Statements for Dr. Reddy's Laboratories

Annual Cash Flow Statements for Dr. Reddy's Laboratories

Quarterly Cash Flow Statements for Dr. Reddy's Laboratories

Annual Balance Sheets for Dr. Reddy's Laboratories

Quarterly Balance Sheets for Dr. Reddy's Laboratories

Annual Metrics And Ratios for Dr. Reddy's Laboratories

Quarterly Metrics And Ratios for Dr. Reddy's Laboratories

Frequently Asked Questions About Dr. Reddy's Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools